Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VDR | P11473 | 12/20 | 0.52 |
| ▸ | CDC25A | P30304 | 2/20 | 0.51 |
| ▸ | CDC25B | P30305 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 3/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | SREBF1 | P36956 | 1/20 | 0.48 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.47 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.47 |
| ▸ | GC | P02774 | 1/20 | 0.47 |
| ▸ | PGR | P06401 | 1/20 | 0.47 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.47 |
| ▸ | RXRA | P19793 | 1/20 | 0.47 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.47 |
| ▸ | CNR1 | P21554 | 1/20 | 0.47 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.47 |
| ▸ | HTR2C | P28335 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.47 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.47 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25891893 | 1.00 | VDR (0.52) | VDRCDC25ACDC25BMAPTSMN1; SMN2 | |
| SCHEMBL22679443 | 1.00 | VDR (0.52) | VDRCDC25ACDC25BMAPTSMN1; SMN2 | |
| SCHEMBL26323394 | 1.00 | VDR (0.52) | VDRCDC25ACDC25BMAPTSMN1; SMN2 | |
| SCHEMBL6732712 | 1.00 | VDR (0.52) | VDRCDC25ACDC25BMAPTSMN1; SMN2 | |
| SCHEMBL3981068 | 0.90 | VDR (0.51) | VDRCDC25ACDC25BMAPTSMN1; SMN2 | |
| SCHEMBL14259155 | 0.90 | VDR (0.51) | VDRCDC25ACDC25BMAPTSMN1; SMN2 | |
| SCHEMBL29481140 | 0.89 | CDC25A (0.67) | VDRCDC25ACDC25BMAPTSMN1; SMN2 | |
| SCHEMBL13841867 | 0.86 | VDR (0.50) | VDRCDC25ACDC25BMAPTSMN1; SMN2 | |
| SCHEMBL25891913 | 0.86 | CDC25A (0.46) | VDRCDC25ACDC25BMAPTSMN1; SMN2 | |
| SCHEMBL3903380 | 0.86 | CDC25A (0.55) | VDRCDC25ACDC25BMAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1061070-B1 | Process for the preparation of ED-71 | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2008-07-16 | — | — | EP | disclosed |
| US-6538145-B2 | Having a hydroxy group at 24-position and, optionally, a substituent at 2 beta position; reacting intermediates of the A ring part and intermediates of the C ring; cyclization; coupling; control of calcium metabolism; antitumor agents | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2003-03-25 | — | — | US | disclosed |
| US-20020094972-A1 | 24-hydroxy vitamin D derivatives | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2002-07-18 | — | — | US | disclosed |
| EP-1061070-A1 | 24-HYDROXYVITAMIN D DERIVATIVES | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2000-12-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020094972-A1 | 24-hydroxy vitamin D derivatives | CYP24A1, VDR, CYP2R1 | VDR 2/4885CDC25A 1723/4885CDC25B 2256/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.